Overview

Rapamycin in Advanced Cancers

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

The goal of this study is to determine the rapamycin dose equivalent to the recommended phase II/III dose of temsirolimus and determine the observed toxicities and anti-tumor response of rapamycin in patients with advanced cancers.

Phase:

Phase 1

Details

Lead Sponsor:

University of Chicago

Collaborator:

National Institutes of Health (NIH)

Treatments:

Everolimus
Sirolimus